These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164. Shi JA; Lu DL; Huang X; Tan W Int J Mol Med; 2014 Jul; 34(1):237-43. PubMed ID: 24756834 [TBL] [Abstract][Full Text] [Related]
30. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation. Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141 [TBL] [Abstract][Full Text] [Related]
31. Microarray discovery of new OGT substrates: the medulloblastoma oncogene OTX2 is O-GlcNAcylated. Ortiz-Meoz RF; Merbl Y; Kirschner MW; Walker S J Am Chem Soc; 2014 Apr; 136(13):4845-8. PubMed ID: 24580054 [TBL] [Abstract][Full Text] [Related]
32. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241 [TBL] [Abstract][Full Text] [Related]
33. MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells. Panwalkar P; Moiyadi A; Goel A; Shetty P; Goel N; Sridhar E; Shirsat N J Mol Neurosci; 2015 Jul; 56(3):673-80. PubMed ID: 25859932 [TBL] [Abstract][Full Text] [Related]
34. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma. Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590 [TBL] [Abstract][Full Text] [Related]
35. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma. Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617 [TBL] [Abstract][Full Text] [Related]
36. Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. Morrison LC; McClelland R; Aiken C; Bridges M; Liang L; Wang X; Di Curzio D; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE Neoplasia; 2013 Apr; 15(4):384-98. PubMed ID: 23555184 [TBL] [Abstract][Full Text] [Related]
37. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Di C; Liao S; Adamson DC; Parrett TJ; Broderick DK; Shi Q; Lengauer C; Cummins JM; Velculescu VE; Fults DW; McLendon RE; Bigner DD; Yan H Cancer Res; 2005 Feb; 65(3):919-24. PubMed ID: 15705891 [TBL] [Abstract][Full Text] [Related]
38. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor. Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Bai R; Siu IM; Tyler BM; Staedtke V; Gallia GL; Riggins GJ Neuro Oncol; 2010 Jul; 12(7):655-63. PubMed ID: 20511190 [TBL] [Abstract][Full Text] [Related]
40. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. de Haas T; Oussoren E; Grajkowska W; Perek-Polnik M; Popovic M; Zadravec-Zaletel L; Perera M; Corte G; Wirths O; van Sluis P; Pietsch T; Troost D; Baas F; Versteeg R; Kool M J Neuropathol Exp Neurol; 2006 Feb; 65(2):176-86. PubMed ID: 16462208 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]